Technical analysis of Cytokinetics, Incorporated (CYTK): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Price Performance
| 1 month | -8.82% |
| 3 months | -11.92% |
| Year-to-date | +9.21% |
| 1 year | +45.90% |
| 3 years | +104.87% |
52-Week Range
| 52-week High | $88.31 |
| 52-week Low | $47.22 |
| Avg Volume (90d) | 2.1M |
Technical Indicators
| SMA 50 | $77.40 |
| SMA 200 | $69.99 |
| Beta | 0.48 |
| 30-day Volatility (annualised) | 39.3% |
| Price vs SMA 50 | -10.3% |
| Price vs SMA 200 | -0.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $63.59 | |
| 2025-11 | $68.13 | +7.1% |
| 2025-12 | $63.54 | -6.7% |
| 2026-01 | $63.19 | -0.6% |
| 2026-02 | $62.22 | -1.5% |
| 2026-03 | $65.91 | +5.9% |
| 2026-04 | $63.97 | -2.9% |
| 2026-05 | $76.76 | +20.0% |
| 2026-06 | $85.19 | +11.0% |
| 2026-07 | $77.13 | -9.5% |
| 2026-08 | $70.91 | -8.1% |
| 2026-09 | $69.39 | -2.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $69.39 |
| Market Cap | $8.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -52.77 |
| EV / EBITDA | -11.34 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -7.32 |
| Current Ratio | 6.66 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.99 |